We are honored to announce the promotion of Landon Merrill to Partner! ??? With over two decades of leadership in life sciences, Landon has played a critical role in shaping Genoa’s mission to build the next generation of transformative companies at the convergence of biology and technology. From his early days pioneering NGS sequencing at Harvard Partners to driving innovative product launches at 10x Genomics, Landon’s expertise has been instrumental in advancing groundbreaking solutions. His strategic insight, deep technical knowledge, and passion for science have been key in assisting Genoa’s portfolio companies to date and will continue to drive success in his new role. As Partner, we know Landon will keep pushing the boundaries of science-driven investing and empowering visionary entrepreneurs to create lasting impact. ???? Landon joins Jenny Rooke and Vikram Chaudhery on our team of Investing Partners. The firm now boasts a 10-person investment team with deep scientific expertise and extensive operating experience, and collectively offers unparalleled insights into building high-impact companies at the convergence of biology and technology. Read more in today’s press release:?? https://lnkd.in/ejTyucVD
Genoa Ventures
风险投资与私募股权管理人
San Francisco，CA 2,226 位关注者
Investing Where Biology and Technology Converge
关于我们
Genoa Ventures invests in early-stage companies innovating at the convergence of biology and technology. Visionary startups developing innovative life science technologies with outsized potential often struggle to raise capital from traditional funders. These companies are typically multi-disciplinary (e.g. genomics + optics + microfluidics + big data) and/or market-making, and don't neatly fit most VC’s patterns and boxes. Genoa Ventures stands in this gap. Genoa Ventures uniquely combines an appetite for technology-driven, “category-defying” opportunities in life sciences with the domain expertise and operational experience necessary to select and nurture the best bio-based companies early, before most other investors. We take the time to understand the science and technology, applications and markets, and to help these companies achieve their full potential. We believe in the enormous and relatively untapped possibilities of life science technologies and discoveries applied to realms outside of healthcare, and in the unbounded potential of the entrepreneurial visionaries who will lead us in realizing these possibilities.
- 网站
-
https://www.genoavc.com
Genoa Ventures的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 2-10 人
- 总部
- San Francisco，CA
- 类型
- 合营企业
- 创立
- 2018
- 领域
- synthetic biology、genomics、genetics、research tools、venture capital、Seed、Series A、diagnostics、agriculture、go-to-market strategy和cytometry
地点
-
主要
获取路线
NA
US，CA，San Francisco，94110
Genoa Ventures员工
动态
-
This week at American College of Rheumatology Convergence 2024, #GenoaPortCo Aqtual, Inc. announced updates to its first-of-its-kind blood-based test for rheumatoid arthritis therapy selection. Maggie Louie, VP of Translational Research, presented two posters. Poster 1: Proof-of-concept data demonstrating Aqtual's blood-based therapy selection test can predict treatment response in patients with Rheumatoid Arthritis.? Poster 2: An interim analysis from PRIMA-102, Aqtual's prospective observational clinical trial that has enrolled more than 1000 patients to date, with more than 500 patients completing the study follow-up period. The presentation demonstrated how their blood test could shape treatment decisions, potentially reducing the lengthy trial-and-error process that rheumatoid arthritis patients often face. Discover more about their blood tests here: https://lnkd.in/eeDiCnfS
What an exciting weekend at #ACR24 in Washington, DC! We’re thrilled to share that our poster was selected for the prestigious ACR Poster Tour—a proud moment for Aqtual. Our VP of Translational Research, Maggie Louie, had the honor of presenting our groundbreaking work to fellow colleagues in the rheumatology field. Learn more about our data presentations and how they align with our mission to launch the first RA therapy selection test in 2025—offering a positive prediction of drug-class-specific therapy response for patients:?https://lnkd.in/eeDiCnfS
-
-
?? Fellow has processed 100,000 test results and counting! This is a major milestone for this #GenoaPortCo. Since 2020, they have provided the only peer-reviewed, mail-in semen analysis to an enormous number of patients. Fellow collaborates with over 1,500 clinical practices to empower patients to take charge of their reproductive health, handling more than 300 patient samples each day in their CLIA-certified laboratory. Continue watching as they change the standards for male fertility. #menshealth #reproductivehealth #FellowHealth #biotech
We’re thrilled to announce a major milestone at Fellow: over 100,000 patient tests completed! ?? Thank you to our dedicated team, our valued clinic partners, and every patient who trusts us. Each test stands for quality, accuracy, and accessibility. Together, we’re shaping the future of men’s health, one test at a time. Here’s to the next 100,000 and beyond! #FellowHealth #Innovation https://lnkd.in/ekd5R2As
-
This November, Codetta Bio?, a #GenoaPortCo, is offering a limited-time research opportunity through their Technology Access Program (TAP) – free of cost. With this program, you can explore Codetta Bio Sonata Services and help scientists accelerate discoveries in cancer research. One of their key offerings is the 4-Plex Cytokine Assay, which measures four important immune system proteins—IL-2, IL-4, IL-6, and IL-7. In addition to this, there is the Omics Assay, which is a service that allows researchers to measure both proteins and DNA/RNA? from the same sample. Learn more about their offerings here!
Supporting Movember’s Mission through Enhanced Cancer Research We’re proud to support Movember by advancing cytokine research that aligns with its mission to improve men’s health. Our IL-2, IL-4, IL-6, and IL-7 cytokine panel offers researchers a specialized tool for innovative studies that could lead to breakthrough insights in men’s cancer, reduce mortality, and ultimately enhance outcomes. In support of Movember, we’re offering researchers a free opportunity to try our cytokine service to accelerate discoveries in cancer research. Apply now: https://hubs.ly/Q02WXBtP0
-
-
Growing with the Future! ?? Congratulations are in order for Gaganpreet Sidhu, the new #CTO at Meiogenix We love seeing leaders grow and achieve their full potential in our #portcos! Their success is intertwined with and fuels the success of the company. That close ink is central to what makes startups so exciting and impactful.?
We are excited to announce that?Dr.?Gaganpreet Sidhu?will assume the position of Chief Technology Officer at Meiogenix! ? With a PhD from Cornell University and a postdoctoral training at Columbia University, Dr. Sidhu brings a remarkable depth of experience to this role. Her expertise spans DNA repair and recombination research across a variety of species, including wheat, maize, tomato, xenopus among others. ? Dr. Sidhu has been an integral member of Meiogenix, driving scientific advancements in targeted recombination to unlock plant genetic diversity. She has been instrumental in demonstrating proof of concept of Meiogenix Technology in plants. ? In addition to her research accomplishments in Meiogenix, Dr. Sidhu actively engages with the scientific community, has served as an editor for Frontiers in Plant Science, and has organized several international conferences with the Federation of American Societies for Experimental Biology (FASEB) to promote global collaboration in the plant meiotic recombination field. ? We’re thrilled to see her take on this leadership role as we work together to unlock natural genetic diversity in crops and deliver innovative solutions for agriculture. ? Congratulations, Dr. Sidhu!
-
-
?? Tomorrow, November 13th at 6:30pm CST?? Curious about what it takes to build a successful biotech startup that makes a global impact? Attend a live webinar hosted by SWAN Genomics, featuring William (Bill) Hyun PhD, Co-Founder of Swan Genomics and Venture Partner at Genoa Ventures. Bill, along with other members of SWAN Genomics, will share their life-long expertise, drawing from his extensive experience as a founder, investor, and advisor to over 50 companies. He has also authored over 100 peer-reviewed publications. Gain firsthand insight into how leading innovators in medicine are developing solutions that make a meaningful impact on the world. Link to attend: https://lnkd.in/eXGCcUJ9
Excited to invite you to an exclusive event at the Michael Crouch Innovation Centre: From Genomics Research to Global Impact. Join us for a deep dive into how biotech startups have propelled DNA sequencing from the days of the Human Genome Project to the cutting-edge advancements of Next-Gen and Long Read Sequencers. This is more than just an industry panel – it's a look into the journeys, ideas, and insights from those pioneering the future of genomics. Panelists: Brock Siegel, William (Bill) Hyun, Morassa Mohseni, PhD ??, David Hsu, and Lawrence Lee #BiotechStartups #genomicsinnovation ##TechInGenomics
此处无法显示此内容
在领英 APP 中访问此内容等
-
Want to lower your OPEX and reduce RO membrane cleaning frequency in landfill leachate? Join us next Tuesday, November 12, for an insightful webinar on advanced RO membrane technology in landfill leachate treatment! Key takeaways: ?? How ZwitterCo RO has reduced cleaning frequency and cut costs across various leachate sites ?? How advanced RO membranes can help you achieve your discharge or water reuse goals ?? How to reduce RO cleanings, lower OPEX, and increase sustainability in your operations ??? Date: November 12, 2024 ? Time: 2:00 PM EST ?? Register here: https://lnkd.in/eh82FTdW See you next week!
-
-
Have a passion for plant pathology? #GenoaPortCo Tropic is looking for a scientist to conduct contained disease assays on tropical plants. Want to transcript the future of science? Alida Biosciences is looking for a software engineer to drive the development of cutting-edge applications, data processing pipelines, and data storage solutions for bioinformatics. Interested in other openings at Genoa Ventures’s portfolio companies of consequence? We’ve just launched a new feature on our website dedicated to career opportunities working alongside the world’s most visionary scientific entrepreneurs! The Genoa job board provides a convenient way for anyone interested in #GenoaPortCos to explore all of the listings in one place. Find out more and apply now: https://lnkd.in/emAwRmAa
-
-
SimBioSys, Inc. knows the significance of pairs and announced two big achievements this week! This #GenoaPortCo received their 2nd FDA 510(k) clearance for TumorSight? Viz, expanding its use by breast surgeons across the United States. The updated TumorSight Viz now processes images with AI in a matter of minutes, integrates enhanced AI-driven tumor segmentation, enables seamless access to MRI images through direct connectivity to PACS systems, and has a first-of-its-kind clinical decision support (CDS) feature that informs providers of evidence-based treatment options. In other news, NVIDIA published a blog post recognizing SimBioSys as an exemplary startup for creating their technology – TumorSight Viz, a 3D visualization tool. Surgeons often lack an abundance of information about tumors from radiology reports and frequently seek additional details from the radiologists report. However, they are not always able to engage in in-depth discussions or access the radiologists before surgery. This blog post highlights the use cases of their technology, which provides more data regarding the size, volume, and other key measurements that surgeons can access immediately. Read more in the links below: Linkedin: https://lnkd.in/eeTp44pE Press Release: https://lnkd.in/euYXmQCc
SimBioSys Achieves Second FDA Clearance for TumorSight? Viz and Introduces TumorSight? Clinical Decision Support for Breast Cancer Surgery
prnewswire.com
-
Congratulations to Epitel for their big win! The 2024 Digital Health Hub Foundation awarded the Digital Health Awards in the Rising Star - Home Health Diagnostics to this #GenoaPortco for their fully wireless REMI? Remote EEG Monitoring System. With November being Epilepsy Awareness Month, Epitel is proud to be developing technologies that will benefit millions of people living with epilepsy, seizures and other neurological diseases. These efforts are setting a new standard and raising awareness for brain health in the life sciences industry.
We are extremely proud to announce that Epitel has won The Digital Health Hub Foundation - Digital Health Awards 2024 in the Home Health Diagnostics “Rising Star” category. Thank you to the Digital Health Hub Foundation and the team at HLTH Inc. We want to recognize others in this category and the incredible work of our fellow finalists:? Daye SonarMD Rune Labs Circadian Health Bodyport Mindstep HeartBeam Inc. (NASDAQ: BEAT) Starling (YC W22) Remember:? ?? Each year, 13M people in the US are suspected of a seizure, yet seizure detection remains a noticeable gap in our healthcare ecosystem.? ?? Access to EEG is limited, with only 40% of people who qualify for an EEG actually getting one due to lack of access. ?? Outpatient ambulatory monitoring for greater than 3 days is rarely possible, resulting in missed diagnoses and under and over treatment. We are on a mission to change this. Epitel equips healthcare providers with the ability to offer remotely accessible, affordable, and reliable EEG monitoring enabled by powerful FDA-cleared AI. We are empowering better brain health solutions and treatment decisions by making EEG readily accessible, deployable, and equitable. Epitel will demonstrate the power of the REMI System at its kiosk in the Awards Pavilion #3254-14. For more information on REMI and Epitel, please visit www.epitel.com #RisingStar #Seizure #homehealth #HLTH2024 #EEG
-